STUDY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLUL

索拉非尼治疗晚期肝细胞癌患者的研究

• 批准号: 7603805
• 负责人: JORGE A MARRERO
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603805
• 关键词: BAY 54-9085; Cancer Patient; Computer Retrieval of Information on Scientific Projects Database; Data; Funding; Grant; Institution; Life; Malignant neoplasm of liver; Patients; Pharmaceutical Preparations; Phase; Placebos; Purpose; Research; Research Personnel; Resources; Source; Tablets; United States National Institutes of Health; cancer type; chemotherapy; pill; sugar

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to assess if a new drug, sorafenib, is an effective treatment for patients with liver cancer. Subjects in this study received either sorafenib or placebo (a tablet that looks identical to sorafenib but contains no active drug). To date, over 8787 cancer patients have taken sorafenib either as a lone treatment or together with other chemotherapy drugs for several different types of cancer. Following a review of the data collected from this study so far, a significant difference was noticed in the overall survival between patients receiving sorafenib and patients receiving placebo (sugar pill that looks like sorafenib). Those patients taking sorafenib lived longer on average compared to patients taking placebo. As a result the crossover phase of the study has begun where subjects taking sorafenib have been offered the option to continue taking sorafenib. Subjects taking placebo have been offered the option to begin taking sorafenib. This crossover phase of the study will continue until an alternative supply of sorafenib treatment outside of the study is made available.'

这个子项目是众多研究子项目之一